Study of sinonasal cancer outcomes and quality of life
Official title: Sinonasal Cancer Study to Evaluate Oncologic Outcomes and Quality of Life
Run by Mayo Clinic · NCT04755855 · Data updated 2026-11-12
This study looks at how sinonasal cancer affects patients' lives and treatment results to help improve future care for those diagnosed with this type of cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 30 Days to 99 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Status | Recruiting |
| Started | January 1, 2021 |
| Main results expected | January 2031 |
| Study ends | January 2031 |
| Registry record updated | April 3, 2026 |
| Trial ID | NCT04755855 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients aged between 30 days and 99 years who have been diagnosed with sinonasal cancer and are receiving treatment at the Mayo Clinic.
✕Probably not a fit
Patients who are healthy or unwilling to provide informed consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study involves multiple institutions focusing on patients diagnosed with sinonasal carcinoma. It aims to gather data on the progression of sinonasal cancer, treatment outcomes, and the quality of life of affected patients. Additionally, the study will conduct central mutational and genomic analyses of tumor tissues to better understand the disease. By collecting this information, the study seeks to enhance knowledge and improve future treatment strategies for sinonasal cancer.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment approaches and better quality of life for patients with sinonasal cancer.
How similar studies have gone: While this study is focused on sinonasal cancer, similar multi-institutional studies have shown success in understanding cancer outcomes and improving patient care.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects between the ages of 30 days (non-inclusive) and 99 years (inclusive) * Patients with a diagnosis of sinonasal cancer * Patients undergoing treatment at Mayo Clinic Exclusion Criteria: * Healthy individuals * Unwilling to sign the informed consent
Where it's running
-
Mayo Clinic in Rochester
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Jake Eide, MD — Mayo Clinic
- Study coordinator: Clinical Trials Referral Office
- Email: mayocliniccancerstudies@mayo.edu
- Phone: 855-776-0015
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma
This study tests how well patients with T4 sinonasal adenoid cystic carcinoma tolerate the standard treatment of surgery followed by postoperative radiotherapy and what their 3-year progression-free survival looks like.
-
Surgery Alone or with Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma
This study tests whether watching closely after surgery is as safe as adding postoperative radiotherapy for adults with completely removed (R0) early-stage sinonasal adenoid cystic carcinoma.
-
Becotatug vedotin plus epirubicin before surgery for EGFR-positive unresectable recurrent sinonasal adenoid cystic carcinoma
This will test whether combining becotatug vedotin with epirubicin can shrink EGFR-positive, unresectable recurrent sinonasal adenoid cystic carcinoma enough to allow surgery or improve disease control.
-
Epirubicin chemoembolization to shrink sinonasal adenoid cystic carcinoma
This treatment tries three sessions of targeted transarterial Epirubicin chemoembolization in people with locally advanced sinonasal adenoid cystic carcinoma to shrink tumors and decide if surgery can be avoided.
-
Toripalimab plus carboplatin and docetaxel before surgery for sinonasal cancer
This study tests whether giving toripalimab with carboplatin and docetaxel before surgery helps people with locally advanced sinonasal cancers.
-
Radiation plus tarlatamab for DLL3-expressing tumors
This trial will test whether giving tarlatamab together with standard palliative or consolidative radiation is safe for adults with DLL3-expressing or DLL3-prevalent tumors such as melanoma, medullary thyroid cancer, sinonasal undifferentiated carcinoma, esthesioneuroblastoma, and bladder cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.